Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The CH CARE study collects biospecimens and clinical data from adults with solid tumors who plan to receive cytotoxic therapy. Researchers will analyze molecular features to identify high-risk clonal hematopoiesis and its association with therapy-related myeloid neoplasms. The goal is to develop a risk prediction algorithm to identify patients at highest risk and to explore ways to intercept progression from CH to t-MNs. About 5,000 participants are expected to contribute samples such as blood or buccal swabs. This observational study will use collected data to better understand how CH may influence treatment outcomes and long-term risks.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants to be included in this study include the following:
* Adults age \>18 years
* Diagnosed with solid malignancy (breast, ovarian, lung, gastric, colorectal, esophageal, uterine, head and neck, or sarcoma cancers)
* Have a pending plan to receive chemotherapy or radiation for their solid malignancy (cancer).
* Has not received cytotoxic chemotherapy or radiation for their solid cancer diagnosis in the past.

Exclusion Criteria:

* Individuals without plans for cytotoxic chemotherapy, radiation or PARP inhibitor exposure
* Individuals who have received prior chemotherapy and or radiation for their current solid malignancy (cancer)
* Individuals with any prior history of blood cancer (leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, including smoldering multiple myeloma). Persons with blood cancer precursors including clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of uncertain significance (CCUS), monoclonal B lymphocytosis (MBL), monoclonal gammopathy of uncertain significance (MGUS) are eligible for study participation.

Where it's running

• Dana-Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Lachelle D Weeks, MD, PhD — Dana-Farber Cancer Institute
• Study coordinator: Cindy Amaya Lopez, BA
• Email: DFCICHCARESTUDY@DFCI.HARVARD.EDU
• Phone: 857-215-1943

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Riluzole to prevent thinking and memory problems during chemotherapy

  This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07447050

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues

  This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06580002

• Combining local ablative therapy with ongoing systemic treatment for certain cancers

  This study is testing whether adding local treatments to ongoing cancer therapy can help people with certain solid tumors live longer without their disease getting worse.

  Recruiting University of California, Davis · Sacramento, California · NCT06103669

• Validation of a blood test for early cancer detection and monitoring

  This study is testing a blood test to see if it can help find different types of cancer early and monitor patients after treatment.

  Recruiting at 3 sites Adela, Inc · Duarte, California and 16 other locations · NCT05366881

• Combination therapy using checkpoint inhibitors for advanced solid tumors

  This study is testing a new combination treatment using special antibodies for people with advanced solid tumors like lung and liver cancer to see if it can be safer and more effective than current options.

  Recruiting Phase 1/2 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT05187338

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.